Eris Lifesciences Limited has announced the resignation of Mr. Krishnakumar Vaidyanathan from his position as Executive Director & Chief Operating Officer (COO). He has decided to step down to pursue external professional opportunities. The company’s Chairman has accepted the resignation, and Mr. Vaidyanathan will be relieved of his duties effective September 30, 2026. The company expressed gratitude for his contributions.
Executive Leadership Change at Eris Lifesciences
Eris Lifesciences Limited has formally notified the stock exchanges regarding a significant change in its executive leadership. Mr. Krishnakumar Vaidyanathan has tendered his resignation from the crucial roles of Executive Director and Chief Operating Officer (COO) of the company. This decision marks a notable shift in the company’s operational leadership.
Reasons for Resignation and Effective Date
According to the official communication, Mr. Vaidyanathan’s departure is driven by his decision to pursue professional opportunities outside of Eris Lifesciences. The resignation has been formally accepted by the Chairman of the Board. Consequently, the company has determined that Mr. Vaidyanathan will be relieved of all his duties and responsibilities effective from the close of business hours on September 30, 2026.
Company Acknowledgment and Appreciation
Eris Lifesciences has taken the opportunity to publicly acknowledge and express its sincere appreciation for Mr. Krishnakumar Vaidyanathan’s tenure. The company highlighted his valuable contributions, leadership, and dedication throughout his service. The announcement ensures transparency regarding this executive transition as per regulatory requirements.
Disclosure Details
In line with regulatory mandates, the company has provided specific details concerning this change. The reason for the change is cited as a resignation to pursue professional opportunities outside the company. The effective date of cessation is September 30, 2026. Further details regarding Mr. Vaidyanathan’s profile or relationships with other directors were noted as ‘Not Applicable’ for this disclosure context.
Source: BSE
